Drug Profile
LSL 90202
Latest Information Update: 03 Sep 1998
Price :
$50
*
At a glance
- Originator Ipsen Pharma SA
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 03 Sep 1998 No-Development-Reported for Hyperlipidaemia in Spain (Unknown route)
- 10 Mar 1995 Preclinical development for Hyperlipidaemia in Spain (Unknown route)